The link you have chosen leads to a site maintained by a third party over whom Bracco Imaging has no control. As such, Bracco Imaging makes no representation as to the accuracy or any other aspect of the information on this site. The clinical use of Bracco Imaging Products in these pages may not be consistent with the approved indications.

The information on this site is not country specific and may contain information that is outside the approved indication where you practice.

Research & Clinical Development

Our Commitment to R&D and Innovation

Bracco Imaging devotes considerable effort and substantial resources to research and development (R&D), in order to create and develop innovative products addressing unmet or poorly met medical needs. Another R&D goal is the conception and implementation of high-efficiency production processes with special attention to minimise their environmental impact.

Bracco Imaging carries out its R&D activities in the Research Centers of Colleretto Giacosa (Ivrea, Italy) and Plan-les-Ouates (Geneva, Switzerland).

Our Group currently owns approximately 1,500 patents registered throughout the world. Our history of developing proprietary products includes: Isovue® (iopamidol injection), the first ready-to-use, non-ionic / low osmolar contrast agent for X-Ray, launched in 1981 and still the leading product in many markets under different brand names; MultiHance® (gadobenate dimeglumine) injection, 529 mg/mL, the magnetic resonance imaging (MRI) contrast agent with high relaxivity and dual route of excretion, launched in 1998; and obtained approval for expanded labeling in magnetic resonance angiography (MRA) in 2012; and CardioGen-82® (Rubidium Rb 82 Generator), the first agent approved in the U.S. for cardiac positron emission tomography (PET) myocardial perfusion imaging (MPI).

The Group is currently engaged in the development of new imaging agents and solutions, specifically designed to improve patient management through increased accuracy in diagnoses.